News and Events

To overcome the limits of single-target therapies, drug developers are increasingly using multispecific antibodies to hit multiple pathways and cell types with one molecule. William Roach shows how Adimab's anti-CD3 and anti-TCR binders, paired with novel heterodimerization solutions, drive design and development of multispecific T-cell engagers.